Figure 7.

The role of risk score in the prediction of immunotherapeutic benefits. (A) Kaplan-Meier curves for patients with high and low risk score in the IMvigor210 cohort. (B) Rate of clinical response (complete response [CR]/partial response [PR] and stable disease [SD]/progressive disease [PD] to anti-PD-L1 immunotherapy in high and low risk score subgroups in the IMvigor210 cohort). (C) Violin plots depicted the differences in risk score in good prognosis and poor prognosis’ groups in the GSE148476 cohort. p < 0.001. (D) Alluvial diagram of m6A clusters distribution in groups with different clusters, risk score, immune infiltration, and survival outcomes. From the outside to the inside, each ring represents Cluster, risk group, immune infiltration, and survival status, respectively. (E) Kaplan-Meier curves for patients in the training cohort stratified by groups with different m6A gene clusters and risk score.